1 – 10 of 31
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
- Contribution to journal › Article
- 2022
-
Mark
Mental health and psychosocial consequences linked to radiation emergencies - Increasingly recognised concerns
- Contribution to journal › Scientific review
-
Mark
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors : Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
- Contribution to journal › Article
- 2021
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
- Contribution to journal › Article
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
- Contribution to journal › Article
- 2017
-
Mark
Kronisk myeloisk leukemi : förebild för målstyrd terapi - Revolutionerande överlevnadsvinster med definitiv bot i sikte och kraftigt förbättrad hälsoekonomi
- Contribution to journal › Article
-
Mark
Kronisk myeloisk leukemi : Förebild för målstyrd terapi
- Contribution to journal › Debate/Note/Editorial
-
Mark
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia
- Contribution to journal › Article
-
Mark
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia
- Contribution to journal › Article